Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis
Open Access
- 29 September 2008
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 58 (10) , 2993-2999
- https://doi.org/10.1002/art.23902
Abstract
Objective In rheumatoid arthritis (RA), B cell depletion occurs in all patients treated with rituximab, but the clinical responses to rituximab are variable. A highly sensitive assay was used to test the hypothesis that B cell depletion is variable, and that incomplete depletion leads to a poorer outcome. Methods Sixty patients with active RA unresponsive to anti–tumor necrosis factor agents received two 1‐gram infusions of rituximab. B cell numbers were measured by highly sensitive flow cytometry before and after each infusion and at 3‐month intervals thereafter. A reduction in B cell levels below 0.0001 × 109/liter was defined as complete depletion (compared with 0.05 × 109/liter by conventional cytometry). Clinical responses were measured using the European League Against Rheumatism (EULAR) criteria. Results At 6 months, 92% of patients had a moderate‐to‐good clinical response according to the EULAR criteria. B cells were detected in 63% of patients after the first infusion of rituximab (median level 0.0009 × 109/liter [range 9/liter), and these patients had poorer clinical outcomes than patients with complete depletion. At 9 months, 82% of patients with complete depletion had a moderate‐to‐ good EULAR response, compared with 43% of those with partial depletion (P = 0.01). At 12 months, 59% of complete responders had a moderate‐to‐good EULAR response, compared with 21% of those with partial depletion (P = 0.01). Patients in whom B cells were depleted only after the second infusion did no better than those in whom depletion was never complete and had poorer clinical outcomes than those in whom depletion was initially complete. Conclusion This study is the first to show, using a highly sensitive analysis, that rituximab therapy is associated with variable diminution in B cell numbers. A lack of complete depletion of B cells after 1 infusion was associated with a poorer outcome.Keywords
This publication has 15 references indexed in Scilit:
- Immunohistochemical analysis as a means to predict responsiveness to rituximab treatmentArthritis & Rheumatism, 2007
- International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemiaLeukemia, 2007
- Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimensLeukemia, 2006
- Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy and safety at twenty‐four weeksArthritis & Rheumatism, 2006
- The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: Results of a phase IIB randomized, double‐blind, placebo‐controlled, dose‐ranging trialArthritis & Rheumatism, 2006
- Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged SurvivalJournal of Clinical Oncology, 2005
- The Biology of CD20 and Its Potential as a Target for mAb TherapyPublished by S. Karger AG ,2004
- Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteriaArthritis & Rheumatism, 1996
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995